Assessment of dyslipidemia management in Turkey using a Delphi panel

Basit Öğe Kaydı
dc.authorscopusidTuğba Kemaloğlu Öz / 55804564100
dc.authorwosidTuğba Kemaloğlu Öz / HXI-6000-2023
dc.contributor.authorSinan, Ümit Yaşar
dc.contributor.authorYılmaz, Mehmet Birhan
dc.contributor.authorTemizhan, Ahmet
dc.contributor.authorYüksel, Uygar Çağdaş
dc.contributor.authorGüngör, Barış
dc.contributor.authorKemaloğlu Öz, Tuğba
dc.contributor.authorKuş, Mesut
dc.contributor.authorÖzdoğan, Öner
dc.contributor.authorKayıkçıoğlu, Meral
dc.date.accessioned2025-04-16T20:14:55Z
dc.date.available2025-04-16T20:14:55Z
dc.date.issued2024
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.description.abstractThis study evaluated the management of dyslipidemia in Turkey with the goal of understanding current diagnosis and treatment patterns, as well as identifying unmet needs in achieving effective low-density lipoprotein cholesterol (LDL-C) targets. Using a Delphi panel consisting of nine expert cardiologists, the study reveals key gaps in dyslipidemia management, particularly in the underutilization of combination therapies, such as statins and PCSK9 inhibitors, which are crucial for achieving LDL-C targets in high-risk patients. The findings indicate that while many patients with very high cardiovascular risk are diagnosed, a significant proportion do not receive optimal treatment to reach LDL-C levels recommended by European guidelines. Addressing these gaps could lead to more effective management of dyslipidemia and reduce the burden of cardiovascular disease in Turkey. The study’s insights provide critical recommendations for clinicians and policymakers to improve clinical practice and health outcomes through more aggressive lipid-lowering strategies. © The Author(s) 2024.
dc.description.sponsorshipWe would like to pay our gratitude and respects to Prof. Dr. Oktay \u00D6zdemir from Yorum Consultancy, Istanbul, Turkey who has contributed to the analyses and data acquisition of the present study and has passed away on August 24, 2021. The Delphi Panel was sponsored and funded by Novartis Pharma, Istanbul, Turkey.
dc.identifier.citationSinan, U. Y., Yilmaz, M. B., Temizhan, A., Yuksel, U. C., Gungor, B., Kemaloglu Oz, T., ... & Tokgozoglu, L. (2024). Assessment of dyslipidemia management in Turkey using a Delphi panel. Scientific Reports, 14(1), 31307.
dc.identifier.doi10.1038/s41598-024-82780-2
dc.identifier.issn20452322
dc.identifier.issue1
dc.identifier.pmid39732966
dc.identifier.scopusqualityQ1
dc.identifier.urihttp://dx.doi.org/10.1038/s41598-024-82780-2
dc.identifier.urihttps://hdl.handle.net/20.500.12713/6071
dc.identifier.volume14
dc.identifier.wosWOS:001385899200029
dc.identifier.wosqualityQ1
dc.indekslendigikaynakScopus
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.institutionauthorKemaloğlu Öz, Tuğba
dc.institutionauthoridTuğba Kemaloğlu Öz / 0000-0003-1168-8237
dc.language.isoen
dc.publisherNature Research
dc.relation.ispartofScientific Reports
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCardiovascular Diseases
dc.subjectCholesterol
dc.subjectLDL
dc.subjectDelphi Technique
dc.subjectDyslipidemias
dc.subjectFemale
dc.subjectHumans
dc.subjectMiddle Aged
dc.subjectMale
dc.subjectPCSK9 Inhibitors
dc.titleAssessment of dyslipidemia management in Turkey using a Delphi panel
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Assessment-of-dyslipidemia-management-in-Turkey-using-a-Delphi-panelScientific-Reports (1).pdf
Boyut:
1.35 MB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu